MF
TARS icon

Magnetar Financial’s Tarsus Pharmaceuticals TARS Stock Holding History

Magnetar Financial’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,721
Closed -$596K – 1178
2025
Q2 		$596K Buy
+14,721
New +$662K ﹤0.01% 524

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Magnetar Financial's TARS Position: Q3 2025 in Review

Magnetar Financial sold out of Tarsus Pharmaceuticals (TARS) in Q3 2025, closing a stake of 14,721 shares — an estimated $596K sold.

Magnetar Financial first reported a position in TARS in Q2 2025 and held it in 1 quarter. The position peaked at $596K in Q2 2025. 220 funds tracked by Wall St. Rank hold TARS as of Q3 2025.

  • Magnetar Financial reported no remaining Tarsus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Magnetar Financial sold 14,721 Tarsus Pharmaceuticals shares in Q3 2025, an estimated $596K.
  • Magnetar Financial first reported a position in Tarsus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Magnetar Financial's Tarsus Pharmaceuticals position peaked at $596K in Q2 2025.
  • 220 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2025.

Based on Magnetar Financial's 13F filing for Q3 2025, filed 13 Nov 2025.